{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:50:55Z","timestamp":1794711055892,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011957","name":"Takeda Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pevonedistat is a first-in-class, small molecular inhibitor of NEDD8-activating enzyme that has clinical activity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Preclinical data suggest synergy of pevonedistat with azacitidine and venetoclax.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This single-center, phase 1\/2 study evaluated the combination of azacitidine, venetoclax and pevonedistat in older adults with newly diagnosed secondary AML or with MDS or chronic myelomonocytic leukemia (CMML) after failure of hypomethylating agents. Patients received azacitidine 75\u00a0mg\/m<jats:sup>2<\/jats:sup> IV on days 1\u20137, venetoclax at maximum dose of 200-400\u00a0mg orally on days 1\u201321 (AML cohort) or days 1\u201314 (MDS\/CMML cohort) and pevonedistat 20\u00a0mg\/m<jats:sup>2<\/jats:sup> IV on days 1, 3 and 5 for up to 24 cycles. The primary endpoints for the phase 2 portion of the study were the CR\/CRi rate in the AML cohort and the overall response rate (CR\u2009+\u2009mCR\u2009+\u2009PR\u2009+\u2009HI) in the MDS\/CMML cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Findings<\/jats:title>\n                <jats:p>Forty patients were enrolled (32 with AML and 8 with MDS\/CMML). In the AML cohort, the median age was 74\u00a0years (range 61\u201386\u00a0years), and 27 patients (84%) had at least one adverse risk cyto-molecular feature, including 15 (47%) with a <jats:italic>TP53<\/jats:italic> mutation or <jats:italic>MECOM<\/jats:italic> rearrangement; seventeen patients (53%) had received prior therapy for a preceding myeloid disorder. The CR\/CRi rate was 66% (CR 50%; CRi 16%), and the median overall survival (OS) was 8.1\u00a0months. In the MDS\/CMML cohort, 7 patients (87%) were high or very high risk by the IPSS-R. The overall response rate was 75% (CR 13%; mCR with or without HI 50%; HI 13%). The most common grade 3\u20134 adverse events were infection in 16 patients (35%), febrile neutropenia in 10 patients (25%) and hypophosphatemia in 9 patients (23%). In an exploratory analysis, early upregulation of NOXA expression was observed, with subsequent decrease in MCL-1 and FLIP, findings consistent with preclinical mechanistic studies of pevonedistat. Upregulation of CD36 was observed, which may have contributed to therapeutic resistance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The triplet combination of azacitidine, venetoclax and pevonedistat shows encouraging activity in this very poor-risk population of patients with AML, MDS or CMML.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> ClinicalTrials.gov (NCT03862157).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13045-023-01476-8","type":"journal-article","created":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T13:02:04Z","timestamp":1688821324000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["A phase 1\/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents"],"prefix":"10.1186","volume":"16","author":[{"given":"Nicholas J.","family":"Short","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muharrem","family":"Muftuoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faustine","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Macaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Montalban-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesid","family":"Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Basyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney D.","family":"Dinardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maro","family":"Ohanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghayas C.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Delumpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Abramova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,8]]},"reference":[{"issue":"11","key":"1476_CR1","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1200\/JCO.2014.57.0952","volume":"33","author":"RM Stone","year":"2015","unstructured":"Stone RM, Mazzola E, Neuberg D, et al. Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. J Clin Oncol. 2015;33(11):1252\u20137.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1476_CR2","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"RC Lindsley","year":"2015","unstructured":"Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367\u201376.","journal-title":"Blood"},{"issue":"31","key":"1476_CR3","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","volume":"33","author":"LS Granfeldt Ostgard","year":"2015","unstructured":"Granfeldt Ostgard LS, Medeiros BC, Sengelov H, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33(31):3641\u20139.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1476_CR4","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1182\/bloodadvances.2017008227","volume":"1","author":"P Boddu","year":"2017","unstructured":"Boddu P, Kantarjian HM, Garcia-Manero G, et al. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017;1(17):1312\u201323.","journal-title":"Blood Adv"},{"issue":"1","key":"1476_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-022-01229-z","volume":"15","author":"NJ Short","year":"2022","unstructured":"Short NJ, Venugopal S, Qiao W, et al. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol. 2022;15(1):12.","journal-title":"J Hematol Oncol"},{"issue":"16","key":"1476_CR6","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1002\/cncr.25247","volume":"116","author":"E Jabbour","year":"2010","unstructured":"Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010;116(16):3830\u20134.","journal-title":"Cancer"},{"issue":"24","key":"1476_CR7","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","volume":"29","author":"T Prebet","year":"2011","unstructured":"Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29(24):3322\u20137.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1476_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.blre.2016.09.005","volume":"31","author":"NA Podoltsev","year":"2017","unstructured":"Podoltsev NA, Stahl M, Zeidan AM, Gore SD. Selecting initial treatment of acute myeloid leukaemia in older adults. Blood Rev. 2017;31(2):43\u201362.","journal-title":"Blood Rev"},{"issue":"24","key":"1476_CR9","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1002\/cncr.30220","volume":"122","author":"U Creutzig","year":"2016","unstructured":"Creutzig U, Zimmermann M, Reinhardt D, et al. Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. Cancer. 2016;122(24):3821\u201330.","journal-title":"Cancer"},{"issue":"7","key":"1476_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"issue":"20","key":"1476_CR11","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1002\/cncr.33689","volume":"127","author":"K Kim","year":"2021","unstructured":"Kim K, Maiti A, Loghavi S, et al. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer. 2021;127(20):3772\u201381.","journal-title":"Cancer"},{"issue":"13","key":"1476_CR12","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1182\/bloodadvances.2020001482","volume":"4","author":"BJ Ball","year":"2020","unstructured":"Ball BJ, Famulare CA, Stein EM, et al. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv. 2020;4(13):2866\u201370.","journal-title":"Blood Adv"},{"issue":"2","key":"1476_CR13","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/ajh.26771","volume":"98","author":"AM Zeidan","year":"2023","unstructured":"Zeidan AM, Borate U, Pollyea DA, et al. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. Am J Hematol. 2023;98(2):272\u201381.","journal-title":"Am J Hematol"},{"issue":"12","key":"1476_CR14","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1158\/1078-0432.CCR-09-0343","volume":"15","author":"TA Soucy","year":"2009","unstructured":"Soucy TA, Smith PG, Rolfe M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res. 2009;15(12):3912\u20136.","journal-title":"Clin Cancer Res"},{"issue":"7239","key":"1476_CR15","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nature07884","volume":"458","author":"TA Soucy","year":"2009","unstructured":"Soucy TA, Smith PG, Milhollen MA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009;458(7239):732\u20136.","journal-title":"Nature"},{"issue":"4","key":"1476_CR16","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/bjh.13323","volume":"169","author":"RT Swords","year":"2015","unstructured":"Swords RT, Erba HP, DeAngelo DJ, et al. Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. Br J Haematol. 2015;169(4):534\u201343.","journal-title":"Br J Haematol"},{"issue":"18","key":"1476_CR17","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1182\/blood-2009-11-254862","volume":"115","author":"RT Swords","year":"2010","unstructured":"Swords RT, Kelly KR, Smith PG, et al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood. 2010;115(18):3796\u2013800.","journal-title":"Blood"},{"issue":"9","key":"1476_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","volume":"58","author":"P Bose","year":"2017","unstructured":"Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017;58(9):1\u201317.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"1476_CR19","doi-asserted-by":"publisher","first-page":"825","DOI":"10.3324\/haematol.2020.272609","volume":"107","author":"D Cojocari","year":"2022","unstructured":"Cojocari D, Smith BN, Purkal JJ, et al. Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia. Haematologica. 2022;107(4):825\u201335.","journal-title":"Haematologica"},{"issue":"12","key":"1476_CR20","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/cdd.2015.74","volume":"22","author":"KL Knorr","year":"2015","unstructured":"Knorr KL, Schneider PA, Meng XW, et al. MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors. Cell Death Differ. 2015;22(12):2133\u201342.","journal-title":"Cell Death Differ"},{"issue":"13","key":"1476_CR21","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1182\/blood-2017-09-805895","volume":"131","author":"RT Swords","year":"2018","unstructured":"Swords RT, Coutre S, Maris MB, et al. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood. 2018;131(13):1415\u201324.","journal-title":"Blood"},{"issue":"7","key":"1476_CR22","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1038\/s41375-021-01125-4","volume":"35","author":"MA Sekeres","year":"2021","unstructured":"Sekeres MA, Watts J, Radinoff A, et al. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS\/CMML or low-blast AML. Leukemia. 2021;35(7):2119\u201324.","journal-title":"Leukemia"},{"issue":"20","key":"1476_CR23","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"4","key":"1476_CR24","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347.","journal-title":"Blood"},{"issue":"2","key":"1476_CR25","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419\u201325.","journal-title":"Blood"},{"issue":"12","key":"1476_CR26","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","volume":"125","author":"MR Savona","year":"2015","unstructured":"Savona MR, Malcovati L, Komrokji R, et al. An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults. Blood. 2015;125(12):1857\u201365.","journal-title":"Blood"},{"issue":"3","key":"1476_CR27","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/cncr.30361","volume":"123","author":"F Ravandi","year":"2017","unstructured":"Ravandi F, Jorgensen J, Borthakur G, et al. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer. 2017;123(3):426\u201335.","journal-title":"Cancer"},{"issue":"1","key":"1476_CR28","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/S2352-3026(18)30182-0","volume":"6","author":"NJ Short","year":"2019","unstructured":"Short NJ, Kantarjian HM, Loghavi S, et al. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 2019;6(1):e29\u201337.","journal-title":"Lancet Haematol"},{"issue":"3","key":"1476_CR29","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3324\/haematol.2013.093765","volume":"99","author":"R Luthra","year":"2014","unstructured":"Luthra R, Patel KP, Reddy NG, et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2014;99(3):465\u201373.","journal-title":"Haematologica"},{"issue":"15","key":"1476_CR30","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1056\/NEJMoa1801540","volume":"379","author":"M Muftuoglu","year":"2018","unstructured":"Muftuoglu M, Olson A, Marin D, et al. Allogeneic BK virus-specific T cells for progressive multifocal leukoencephalopathy. N Engl J Med. 2018;379(15):1443\u201351.","journal-title":"N Engl J Med"},{"issue":"1","key":"1476_CR31","doi-asserted-by":"publisher","first-page":"12388","DOI":"10.1038\/s41598-021-91816-w","volume":"11","author":"M Muftuoglu","year":"2021","unstructured":"Muftuoglu M, Li L, Liang S, et al. Extended live-cell barcoding approach for multiplexed mass cytometry. Sci Rep. 2021;11(1):12388.","journal-title":"Sci Rep"},{"issue":"6","key":"1476_CR32","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1191\/1740774505cn121oa","volume":"2","author":"PF Thall","year":"2005","unstructured":"Thall PF, Wooten LH, Tannir NM. Monitoring event times in early phase clinical trials: some practical issues. Clin Trials. 2005;2(6):467\u201378.","journal-title":"Clin Trials"},{"issue":"4","key":"1476_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/sim.4780140404","volume":"14","author":"PF Thall","year":"1995","unstructured":"Thall PF, Simon RM, Estey EH. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med. 1995;14(4):357\u201379.","journal-title":"Stat Med"},{"issue":"17","key":"1476_CR34","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","volume":"6","author":"L Ad\u00e8s","year":"2022","unstructured":"Ad\u00e8s L, Girshova L, Doronin VA, et al. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood Adv. 2022;6(17):5132\u201345.","journal-title":"Blood Adv"},{"issue":"22","key":"1476_CR35","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1002\/cncr.30203","volume":"122","author":"TM Kadia","year":"2016","unstructured":"Kadia TM, Jain P, Ravandi F, et al. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. 2016;122(22):3484\u201391.","journal-title":"Cancer"},{"key":"1476_CR36","doi-asserted-by":"crossref","unstructured":"Richard-Carpentier G, Rausch CR, Sasaki K, et al. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Haematologica. 2023.","DOI":"10.3324\/haematol.2022.282030"},{"key":"1476_CR37","doi-asserted-by":"crossref","unstructured":"Saliba AN, Kaufmann SH, Stein EM, et al. Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. Blood Adv. 2022.","DOI":"10.1182\/bloodadvances.2022008625"},{"issue":"1","key":"1476_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.stem.2016.06.001","volume":"19","author":"H Ye","year":"2016","unstructured":"Ye H, Adane B, Khan N, et al. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche. Cell Stem Cell. 2016;19(1):23\u201337.","journal-title":"Cell Stem Cell"},{"issue":"12","key":"1476_CR39","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","volume":"1","author":"BM Stevens","year":"2020","unstructured":"Stevens BM, Jones CL, Pollyea DA, et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat Cancer. 2020;1(12):1176\u201387.","journal-title":"Nat Cancer"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01476-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-023-01476-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01476-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T13:04:07Z","timestamp":1688821447000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-023-01476-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,8]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1476"],"URL":"https:\/\/doi.org\/10.1186\/s13045-023-01476-8","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,8]]},"assertion":[{"value":"26 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This clinical trial was conducted at a single academic medical center (The University of Texas MD Anderson Cancer Center). The clinical trial was approved by the Institutional Review Board and was conducted in accordance with the Declaration of Helsinki. All participants signed informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N.J.S. and E.J. have received research funding and honoraria from Takeda Oncology. The rest of the authors have no relevant conflicts to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}